Literature DB >> 26060262

Associations between comorbid anxiety, diabetes control, and overall medical burden in patients with serious mental illness and diabetes.

Laura A Bajor1, Douglas Gunzler2, Douglas Einstadter2, Charles Thomas2, Richard McCormick2, Adam T Perzynski2, Stephanie W Kanuch2, Kristin A Cassidy3, Neal V Dawson2, Martha Sajatovic4.   

Abstract

OBJECTIVE: While previous work has demonstrated elevation of both comorbid anxiety disorders and diabetes mellitus type II in individuals with serious mental illness, little is known regarding the impact of comorbid anxiety on diabetes mellitus type II outcomes in serious mental illness populations. We analyzed baseline data from patients with serious mental illness and diabetes mellitus type II to examine relationships between comorbid anxiety, glucose control as measured by hemoglobin A1c score, and overall illness burden.
METHODS: Using baseline data from an ongoing prospective treatment study involving 157 individuals with serious mental illness and diabetes mellitus type II, we compared individuals with and without a comorbid anxiety disorder and compared hemoglobin A1c levels between these groups to assess the relationship between anxiety and management of diabetes mellitus type II. We conducted a similar analysis using cumulative number of anxiety diagnoses as a proxy for anxiety load. Finally, we searched for associations between anxiety and overall medical illness burden as measured by Charlson score.
RESULTS: Anxiety disorders were seen in 33.1% (N=52) of individuals with serious mental illness and diabetes mellitus type II and were associated with increased severity of depressive symptoms and decreased function. Hemoglobin A1c levels were not significantly different in those with or without anxiety, and having multiple anxiety disorders was not associated with differences in diabetes mellitus type II control. However, depressive symptoms were significantly associated with higher hemoglobin A1c levels. Neither comorbid anxiety nor anxiety load was significantly associated with overall medical burden.
CONCLUSION: One in three people with serious mental illness and diabetes mellitus type II had anxiety. Depressive symptoms were significantly associated with Hb1Ac levels while anxiety symptoms had no relation to hemoglobin A1c; this is consistent with previously published work. More studies are needed to better understand the relationship between depression, anxiety, and health management in people with serious mental illness and diabetes mellitus type II.
© The Author(s) 2015.

Entities:  

Keywords:  Serious mental illness; anxiety; bipolar disorder; comorbidity; diabetes mellitus; schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26060262      PMCID: PMC4698974          DOI: 10.1177/0091217415589307

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  47 in total

1.  Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up.

Authors:  D Schoepf; R Potluri; H Uppal; A Natalwala; P Narendran; R Heun
Journal:  Eur Psychiatry       Date:  2011-05-13       Impact factor: 5.361

2.  Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

Authors:  Jeff J Guo; Paul E Keck; Patricia K Corey-Lisle; Hong Li; Dongming Jiang; Raymond Jang; Gilbert J L'Italien
Journal:  J Clin Psychiatry       Date:  2006-07       Impact factor: 4.384

Review 3.  Trauma, PTSD, and the course of severe mental illness: an interactive model.

Authors:  Kim T Mueser; Stanley D Rosenberg; Lisa A Goodman; Susan L Trumbetta
Journal:  Schizophr Res       Date:  2002-01-01       Impact factor: 4.939

Review 4.  Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness.

Authors:  Valerie H Taylor; Roger S McIntyre; Gary Remington; Robert D Levitan; Brian Stonehocker; Arya M Sharma
Journal:  Can J Psychiatry       Date:  2012-01       Impact factor: 4.356

5.  Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort.

Authors:  Steve Brown; Clemence Mitchell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-05-11       Impact factor: 4.328

Review 6.  Prevalence and impact of comorbid anxiety and bipolar disorder.

Authors:  Martin B Keller
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

7.  Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives.

Authors:  Mugdha Gore; Nancy A Brandenburg; Deborah L Hoffman; Kei-Sing Tai; Brett Stacey
Journal:  J Pain       Date:  2006-12       Impact factor: 5.820

Review 8.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

Review 9.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

10.  Correlates of anxiety and depression among patients with type 2 diabetes mellitus.

Authors:  Yatan Pal Singh Balhara; Rajesh Sagar
Journal:  Indian J Endocrinol Metab       Date:  2011-07
View more
  7 in total

1.  Associations among comorbid anxiety, psychiatric symptomatology, and diabetic control in a population with serious mental illness and diabetes: Findings from an interventional randomized controlled trial.

Authors:  Awais Aftab; Chetan Bhat; Douglas Gunzler; Kristin Cassidy; Charles Thomas; Richard McCormick; Neal V Dawson; Martha Sajatovic
Journal:  Int J Psychiatry Med       Date:  2017-12-27       Impact factor: 1.210

Review 2.  Food Insecurity and Diabetes in Developed Societies.

Authors:  Utibe R Essien; Naysha N Shahid; Seth A Berkowitz
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

Review 3.  Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications.

Authors:  Ellen F Charles; Christophe G Lambert; Berit Kerner
Journal:  Int J Bipolar Disord       Date:  2016-07-07

4.  The Mental Status in Patients with Diabetes Mellitus Admitted to a Diabetes Clinic After Presenting in the Emergency Room: The Application of the SCL-90 Scale.

Authors:  Oana Albai; Mirela Frandes; Romulus Timar; Bogdan Timar; Teodora Anghel; Vlad Florian Avram; Alexandra Sima
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-28       Impact factor: 3.168

5.  Measuring Behavior in the Home Cage: Study Design, Applications, Challenges, and Perspectives.

Authors:  Fabrizio Grieco; Briana J Bernstein; Barbara Biemans; Lior Bikovski; C Joseph Burnett; Jesse D Cushman; Elsbeth A van Dam; Sydney A Fry; Bar Richmond-Hacham; Judith R Homberg; Martien J H Kas; Helmut W Kessels; Bastijn Koopmans; Michael J Krashes; Vaishnav Krishnan; Sreemathi Logan; Maarten Loos; Katharine E McCann; Qendresa Parduzi; Chaim G Pick; Thomas D Prevot; Gernot Riedel; Lianne Robinson; Mina Sadighi; August B Smit; William Sonntag; Reinko F Roelofs; Ruud A J Tegelenbosch; Lucas P J J Noldus
Journal:  Front Behav Neurosci       Date:  2021-09-24       Impact factor: 3.617

6.  A study protocol for a non-randomised comparison trial evaluating the feasibility and effectiveness of a mobile cognitive-behavioural programme with integrated coaching for anxious adults in primary care.

Authors:  Eva Szigethy; Francis Solano; Meredith Wallace; Dina L Perry; Lauren Morrell; Kathryn Scott; Megan Jones Bell; Megan Oser
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

7.  Achievement of Adequate Glycemic Control in Patients With Type 2 Diabetes and Comorbid Mental Health Conditions Treated in a Primary Care Setting.

Authors:  Kaitlyn Brown; Katherine Fortenberry; Lisa Gren; Karen Gunning; Carrie McAdam-Marx
Journal:  Diabetes Spectr       Date:  2017-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.